Cargando…

Pulmonary Spindle Cell Carcinoma Presenting Anaplastic Lymphoma Kinase Rearrangement

Pulmonary spindle cell carcinoma is a subtype of pulmonary sarcomatoid carcinoma and a very rare tumor type with a poor prognosis. A few case reports have documented patients with pulmonary sarcomatoid carcinoma with anaplastic lymphoma kinase rearrangement, and the efficacy and outcomes of anaplast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sonehara, Kei, Nozawa, Shuhei, Suzuki, Yusuke, Araki, Taisuke, Komatsu, Masamichi, Tateishi, Kazunari, Hanaoka, Masayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601751/ https://www.ncbi.nlm.nih.gov/pubmed/37900841 http://dx.doi.org/10.1159/000532101

Ejemplares similares

Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non‐small cell lung cancer who subsequently underwent immunotherapy
por: Sonehara, Kei, et al.
Publicado: (2021)

Prognostic implication of erector spinae muscles in non‐small‐cell lung cancer patients treated with immuno‐oncology combinatorial chemotherapy
por: Araki, Taisuke, et al.
Publicado: (2021)

Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
por: Sonehara, Kei, et al.
Publicado: (2022)

Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
por: Sonehara, Kei, et al.
Publicado: (2021)

Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy
por: Araki, Taisuke, et al.
Publicado: (2022)

C‐PLAN index as a prognostic factor for patients with previously untreated advanced non‐small cell lung cancer who received combination immunotherapy: A multicenter retrospective study
por: Sonehara, Kei, et al.
Publicado: (2023)

Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer
por: Sonehara, Kei, et al.
Publicado: (2020)

Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab
por: Araki, Taisuke, et al.
Publicado: (2021)

A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency
por: Sonehara, Kei, et al.
Publicado: (2021)

The efficacy of amrubicin third‐line chemotherapy in patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective and historical study in a single institute
por: Sonehara, Kei, et al.
Publicado: (2019)

Rothia aeria pneumonia in an immunocompetent patient: A novel case study
por: Sonehara, Kei, et al.
Publicado: (2021)

Predictive value of post‐treatment C‐reactive protein‐to‐albumin ratio in locally advanced non–small cell lung cancer patients receiving durvalumab after chemoradiotherapy
por: Araki, Taisuke, et al.
Publicado: (2022)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer
por: Katayama, Ryohei
Publicado: (2018)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Cytomorphological Features of Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Gene Rearrangement
por: Shukla, Saumya, et al.
Publicado: (2019)

Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
por: Kitadai, Rui, et al.
Publicado: (2018)

Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)
por: Araki, Taisuke, et al.
Publicado: (2023)

Control of brain metastases with alectinib in anaplastic lymphoma kinase‐rearranged lung cancer
por: Kwok, Wang Chun, et al.
Publicado: (2017)

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
por: Lin, Liping, et al.
Publicado: (2018)

Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2020)

Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan
por: Maraqa, Bayan, et al.
Publicado: (2022)

Aggressive Inflammatory Myofibroblastic Tumor without Anaplastic Lymphoma Kinase Gene Rearrangement in the Rectum with Liver Metastasis
por: Shimodaira, Yosuke, et al.
Publicado: (2019)

Successful Rescue of Life-threatening Hemoptysis Caused by Pulmonary Tuberculosis Bridging with Extracorporeal Membrane Oxygenation
por: Araki, Taisuke, et al.
Publicado: (2022)

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
por: Seto, Takashi, et al.
Publicado: (2020)

The Usefulness of Straight Chemotherapy for Dermal Exposed Anaplastic Lymphoma Kinase Fusion-Positive Anaplastic Large-Cell Lymphoma with Intracranial Invasion
por: Abe, Hiroyuki, et al.
Publicado: (2019)

Usual Interstitial Pneumonia Pattern Interstitial Lung Disease Developed in a Patient with IgG4-related Chronic Sclerosing Sialadenitis
por: Yamamoto, Hiroshi, et al.
Publicado: (2022)

Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population
por: Ying, Jianming, et al.
Publicado: (2015)

Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
por: Hayashi, Nobuyoshi, et al.
Publicado: (2017)

Metastatic Anaplastic Lymphoma Kinase Rearrangement-Positive Adenocarcinoma of Occult Primary Mimicking Ovarian Cancer
por: Chahin, Michael, et al.
Publicado: (2020)

Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Fukui, Takafumi, et al.
Publicado: (2022)

Correction to: Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2021)

Anaplastic lymphoma kinase–positive anaplastic large cell lymphoma presenting as diffuse pulmonary infiltrates
por: Sato, Shuku, et al.
Publicado: (2020)

Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial
por: Fukano, Reiji, et al.
Publicado: (2020)

Lung Adenocarcinoma with Anaplastic Lymphoma Kinase (ALK) Rearrangement Presenting as Carcinoma of Unknown Primary Site: Recognition and Treatment Implications
por: Hainsworth, John D., et al.
Publicado: (2016)

Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population
por: Lopes, Lisandro F, et al.
Publicado: (2012)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening
por: Lee, Jeeyun, et al.
Publicado: (2015)

Evaluating Solid Lung Adenocarcinoma Anaplastic Lymphoma Kinase Gene Rearrangement Using Noninvasive Radiomics Biomarkers
por: Ma, De-Ning, et al.
Publicado: (2020)

Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy
por: Sasaki, Takaaki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lrb2e4lkn1tautebhof8142hd1